Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a type II protein arginine methyltransferase, is upregulated in numerous ca...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Yaxun Guo, Yuzhan Li, Zhongmei Zhou, Lei Hou, Wenjing Liu, Wenlong Ren, Dazhao Mi, Jian Sun, Xueqin Dai, Yingying Wu, Zhuo Cheng, Tingyue Wu, Qianmei Luo, Cong Tian, Fubing Li, Zhigang Yu, Yihua Chen, Ceshi Chen
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-11-01
Серія:	Journal of Experimental & Clinical Cancer Research
Предмети:	PROTAC PRMT5 KLF5 TNBC
Онлайн доступ:	https://doi.org/10.1186/s13046-024-03237-y
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Схожі ресурси